TABLE 2.
Demographics and Clinical Characteristics | ||
Intermittent infusion (n = 13) | Continuous infusion (n = 5) | |
Male | 8 (62) | 4 (80) |
Age, yr | 69 (61–73) | 67 (49–74) |
BMI, kg/m2 | 22.4 (19.2–30.7) | 31.6 (26.4–42.9) |
SCr at randomization (mg/dL) | 0.67 (0.54–1.09) | 1.21 (0.66–2.16) |
CrCl at randomization (mL/min) | 83.7 (69.4–105.4) | 92 (77.7–222.8) |
CRRT | 5 (38) | 4 (80) |
Comorbidities | ||
Lung cancer | 3 (23) | 1 (20) |
COPD | 2 (15) | 2 (40) |
COVID-19 Coinfection | 1 (8) | 1 (20) |
Beta-lactam at randomization | ||
Cefepime | 7 (54) | 4 (80) |
Meropenem | 2 (15) | 0 (0) |
Piperacillin/tazobactam | 4 (31) | 1 (20) |
Respiratory Isolates, n | ||
Pseudomonas aeruginosa | 7 | 5 |
Klebsiella pneumoniae | 0 | 1 |
Klebsiella aerogenes | 1 | 1 |
Enterobacter cloacae | 2 | 0 |
Proteus mirabilis | 1 | 0 |
Cronobacter sakazakii | 0 | 1 |
Concomitant antibiotics for Gram-negative coverage | ||
Aminoglycoside | 1 (7) | 0 (0) |
Fluoroquinolone | 2 (15) | 0 (0) |
Sulfamethoxazole–trimethoprim | 0 (0) | 1 (20) |
BMI, body mass index; SCr, serum creatinine; CrCl, creatinine clearance; CRRT, continuous renal replacement therapy; COPD, chronic obstructive pulmonary disease.